Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01468324 · ClinicalTrials.gov registry record · Phase 1
AZD7451 for Recurrent Gliomas
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT01468324: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT01468324 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 14 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01468324, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
Background: \- AZD7451 is a drug that may help interfere with brain tumor cell growth. It can prevent glioma cells from entering into normal brain tissue, and slow or stop the growth of additional tumors. Researchers want to see if AZD7451 is effective against gliomas that have not responded to surgery, radiation, or chemotherapy. Objectives: \- To see if AZD7451 is a safe and effective treatment for gliomas that have not responded to standard treatments. Eligibility: \- Individuals at least 18 years of age who have gliomas that have not responded to standard treatments. Design: * Participants will be screened with a physical exam, medical history, blood and urine tests, heart function tests, an eye exam, and imaging studies. * Participants will take AZD7451 daily by mouth for 28-day cycles of treatment. * Participants will keep a medication diary and record any side effects. Treatment will be monitored with frequent blood tests and imaging studies. * Treatment will continue as long as there are no serious side effects and the tumor does not start growing again....
Interventions
- DRUG AZD7451
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2011-10-05 |
| Est. Completion | 2014-04-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01468324
The ClinicalTrials.gov registry entry for NCT01468324 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AZD7451 is the first listed.
NCT01468324 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01468324 about?
NCT01468324 is a clinical study titled "AZD7451 for Recurrent Gliomas". Background: \- AZD7451 is a drug that may help interfere with brain tumor cell growth. It can prevent glioma cells from entering into normal brain tissue, and slow or stop the growth of additional tumors. Researchers want to see if AZD7451 is effective against gliomas that have not responded to sur...
What is the current status of trial NCT01468324?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2011-10-05. Estimated completion is 2014-04-23.
What interventions are being tested in trial NCT01468324?
The interventions under investigation include: AZD7451 (DRUG).
Who is sponsoring clinical trial NCT01468324?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.